Rewind Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
19
- Latest Deal Type
-
Later Stage VC
- Investors
-
9
Rewind Therapeutics General Information
Description
Developer of remyelinating therapeutics designed to facilitate the treatment of neurological diseases. The company's therapeutics system blocks the inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells to promote effective remyelination, enabling medical practitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.
Contact Information
Website
www.rwdtx.comCorporate Office
- Gaston Geenslaan 3
- 3001 Leuven
- Belgium
Corporate Office
- Gaston Geenslaan 3
- 3001 Leuven
- Belgium
Rewind Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC | 25-Jan-2023 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series A1) | 06-Jan-2022 | Completed | Generating Revenue | |||
| 3. Grant | 01-Aug-2019 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 03-Jul-2019 | $10M | $28M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 04-Jan-2018 | $18M | $18M | Completed | Generating Revenue |
Rewind Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Series A | ||||||||
| Series A | 39,953 | $90.46 | $90.46 | 1x | $90.46 | 20.42% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Rewind Therapeutics Comparisons
Industry
Financing
Details
Rewind Therapeutics Competitors (29)
One of Rewind Therapeutics’s 29 competitors is Macomics, a Venture Capital-Backed company based in Edinburgh, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Macomics | Venture Capital-Backed | Edinburgh, United Kingdom | ||||
| SunRegen | Venture Capital-Backed | Reinach, Switzerland | ||||
| Mestag Therapeutics | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| Genespire | Venture Capital-Backed | Milan, Italy | ||||
| Asceneuron | Venture Capital-Backed | Eysins, Switzerland |
Rewind Therapeutics Patents
Rewind Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023401169-A1 | Fused pyrrolyl-sulfonamide compounds | Pending | 02-Dec-2022 | ||
| EP-4626860-A1 | Fused pyrrolyl-sulfonamide compounds | Pending | 02-Dec-2022 | ||
| US-20260184679-A1 | Fused pyrrolyl-sulfonamide compounds | Pending | 02-Dec-2022 | ||
| WO-2024115733-A1 | Fused pyrrolyl-sulfonamide compounds | Inactive | 02-Dec-2022 | ||
| AU-2022285899-A1 | 3-pyrrolylsulfonamide compounds as gpr17 antagonists | Pending | 04-Jun-2021 | A61K31/506 |
Rewind Therapeutics Signals
Rewind Therapeutics Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AXA Investment Managers | Asset Manager | Minority | ||
| Sunstone Life Science Ventures | Venture Capital | Minority | ||
| VLAIO | Limited Partner | |||
| Axxam | PE-Backed Company | Minority | ||
| Boehringer Ingelheim Venture Fund | Corporate Venture Capital | Minority |
Rewind Therapeutics FAQs
-
When was Rewind Therapeutics founded?
Rewind Therapeutics was founded in 2017.
-
Where is Rewind Therapeutics headquartered?
Rewind Therapeutics is headquartered in Leuven, Belgium.
-
What is the size of Rewind Therapeutics?
Rewind Therapeutics has 19 total employees.
-
What industry is Rewind Therapeutics in?
Rewind Therapeutics’s primary industry is Drug Discovery.
-
Is Rewind Therapeutics a private or public company?
Rewind Therapeutics is a Private company.
-
What is Rewind Therapeutics’s current revenue?
The current revenue for Rewind Therapeutics is .
-
How much funding has Rewind Therapeutics raised over time?
Rewind Therapeutics has raised $31.6M.
-
Who are Rewind Therapeutics’s investors?
AXA Investment Managers, Sunstone Life Science Ventures, VLAIO, Axxam, and Boehringer Ingelheim Venture Fund are 5 of 9 investors who have invested in Rewind Therapeutics.
-
Who are Rewind Therapeutics’s competitors?
Macomics, SunRegen, Mestag Therapeutics, Genespire, and Asceneuron are some of the 29 competitors of Rewind Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process